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Summary
Background	&	aims
Home	parenteral	nutrition-quality	of	life	(HPN-QOL©)	is	a	self-assessment	tool	for	the	measurement	of	QOL	in	patients	on	HPN.	The	aims	of	this	study	were:	to	re-assess	the	basic	psychometric	properties	of	the	HPN-
QOL©	in	a	multinational	sample	of	adult	patients;	to	provide	a	description	of	QOL	dimensions	by	short	and	long	HPN	treatment	duration;	to	explore	clinical	factors	potentially	associated	to	QOL	scores.
Methods
Patients	(n	=	699)	from	14	countries	completed	the	HPN-QOL©.	The	questionnaires	were	analysed	to	evaluate	data	completeness,	convergent/discriminant	validity	and	internal-consistency	reliability.	The	association	of
overall	QOL	and	HPN	treatment	duration	as	well	as	other	clinical	factors	were	investigated	using	multivariable	linear	regression	models.
Results
The	analysis	of	the	multitrait-scaling	and	internal	consistency	indicates	a	good	fit	with	the	questionnaire	structure	for	most	items.	Item	discriminant	validity	correlation	was	satisfactory	and	psychometric	evaluation	of
the	HPN-QOL©	in	the	different	English,	French	and	Italian	language	patient	sub-groups	confirmed	psychometric	equivalence	of	the	three	questionnaire	versions.	The	results	of	the	multivariable	linear	regression	showed	that
QOL	scores	were	significantly	associated	with	HPN	duration	(better	in	long-term),	underlying	disease	(better	in	Crohn's	disease	and	mesenteric	ischemiaischaemia)	and	living	status	(worse	in	living	alone)	and,	after	adjusting
for	the	other	factors,	with	the	number	of	days	of	HPN	infusion	per	week.
1	Introduction
Intestinal	failure	is	defined	as	“the	reduction	of	gut	function	below	the	minimum	necessary	for	the	absorption	of	macronutrients	and/or	water	and	electrolytes,	such	that	intravenous	supplementation	is	required	to	maintain
health	and/or	growth”	[1].	Home	parenteral	nutrition	(HPN)	is	the	primary	therapy	of	chronic	intestinal	failure	(CIF)	[2].	The	main	aims	of	HPN	are	to	increase	long	term	survival	of	patients	with	chronic	intestinal	failure	to	improve
quality	of	life	(QOL)	and	to	allow	socio-economic	rehabilitation	[3].	Although	patients	on	HPN	may	not	achieve	complete	return	to	normality,	scores	can	improve	compared	to	pre-HPN	[4].
Although	HPN	is	a	life-saving	therapy	for	patients	with	CIF,	it	does	involve	the	infusion	of	nutrients	into	a	central	vein,	and	can	radically	change	the	life	of	patients	who	may	be	faced	with	on-going	symptoms	of	the	underlying
condition	but	also	live	a	complex,	technology-dependent	lifestyle	[5].	It	is	a	time-consuming,	invasive	therapy	used	in	patients	who	often	have	physical	problems	and	who	have	to	face	many	psychological	difficulties	as	well.	Anxiety	and
fear	are	common	reactions	to	the	threat	of	potentially	life-threatening	complications	of	treatment	such	as	severe	infection,	thrombosis	and	liver	failure	[6],	which	realistically	can	still	occur.	Depression,	anger,	negative	self-image	and
social	 limitations	 are	 frequently	 reported.	Depression	has	 been	 seen	 in	 up	 to	 65%	of	 patients	 on	HPN	and	may	have	 serious	 consequences	 for	 their	 therapy	 as	 it	 has	 been	 shown	 to	 lead	 to	 less	 careful	 catheter	 care	 and	 social
impairment	in	55%	[7].	All	of	these	factors	may	impact	on	QOL.	Severe	fatigue	has	been	reported	as	one	of	the	most	frequent	complaints	-	in	up	to	63%	of	HPN	patients	[8],	which	in	turn	consistently	affect	daily	activities	such	as	work
and	leisure.
In	2012,	the	period	prevalence	of	HPN	in	16	European	countries	was	estimated	to	range	from	3.25	to	66	patients	per	million	of	the	population	[9].	The	most	common	indication	for	HPN	in	adults	is	short	bowel	arising	from
underlying	diseases	such	as	mesenteric	ischemia	ischaemia	and	Crohn's	disease;	motility	disorders	and	bowel	obstruction	due	to	cancer	[7].	About	60–79%	of	patients	in	USA	and	Europe	receiving	HPN	for	CIF	due	to	non	malignant
diseases,	survive	for	five	years	or	more.	At	10	years	84%	are	still	dependent	on	HPN	and	a	significant	number	of	them	live	for	20	years	or	more	[8–14].	In	2009	ESPEN	published	guidelines	for	the	use	of	HPN	in	adults	[15]	recognised
the	lack	of	studies	describing	QOL	in	HPN	patients	using	disease-specific	tools	and	suggested	that	measurement	of	the	QOL	should	be	patient-based	rather	than	the	clinician's	perspective.
The	HPN-QOL©,	a	self	assessment	tool	for	measurement	of	QOL	in	patients	on	HPN,	was	originally	devised	within	the	Home	Artificial	Nutrition	and	Chronic	Intestinal	Failure	(HAN&CIF)	special	interest	group	of	the	European
Society	for	Clinical	Nutrition	and	Metabolism	(ESPEN),	underwent	psychometric	validation	in	a	small	sample	of	English	patients	and	was	then	translated	into	Danish,	Dutch,	French,	German,	Italian,	Polish	and	Spanish	to	allow	for	its
international	use	[16].
Hence	there	is	the	need	of	assessing	the	basic	psychometric	performance	of	the	questionnaire	in	a	larger	number	of	patients	and	of	translations	into	other	languages	as	well	as	to	provide	a	description	of	QOL	dimensions	in	a
sample	of	patients	on	HPN	collected	in	different	European	countries.	Moreover	it	was	deemed	interesting	to	explore	whether	some	factors	appear	to	be	significantly	correlated	with	patterns/items	of	QOL.
Therefore	the	aims	of	the	present	study	are:
1. to	re-assess	basic	psychometric	properties	of	the	HPN-QOL©	in	a	multinational	sample	and	in	three	most	frequent	language	subsamples:	English,	French	and	Italian;
2. to	provide	a	description	of	QOL	dimensions	in	a	sample	of	international	patients,	stratified	by	short	and	long	HPN	treatment	duration;
3. to	explore	clinical	factors	potentially	associated	to	QOL.
2	Methods
2.1	Study	design
This	is	a	cross-sectional	observational	multicentre	study	promoted	by	the	ESPEN	HAN&CIF	working	group	in	fourteen	European,	North	American	and	Australian	countries.	The	research	was	also	supported	by	the	Scientific
Committee	of	ESPEN	which	assigned	a	grant	to	the	principal	investigator	(JB)	of	the	study.	Adult	patients	were	recruited;	eligible	if	they	were	discharged	from	adult	hospital	services	on	HPN.	Patients	were	excluded	if	they	were	unable
to	complete	the	questionnaire	(either	self-administered	or	by	interview)	because	of	mental	impairment.
Conclusions
The	HPN-QOL©,	is	a	valid	tool	for	measurement	of	QOL	in	patients	on	HPN,	to	be	used	in	the	clinical	practice	as	well	as	in	research.
Keywords:	Home	parenteral	nutrition;	Quality	of	life;	Patient	reported	outcomes;	Intestinal	failure
2.2	Quality	of	life	measure	and	data	collection	procedure
The	HPN-QOL©	questionnaire	was	developed	as	a	treatment	specific	instrument	for	the	assessment	of	QOL	in	patients	treated	with	HPN.	It	has	been	translated	into	Danish,	Dutch,	French,	German,	Italian,	Polish	and	Spanish,
using	forward-backward	methodology	[16].	The	French	translation	was	adapted	for	use	in	Belgium	and	French-speaking	Canada	and	the	English	version	adapted	for	use	in	the	US	and	Canada.	Psychometric	small-sample	validation	of
the	English	version	confirmed	the	scale	structure	of	the	questionnaire	[17].
The	questionnaire	contains	7	multi-item	functional	scales	and	1	single-item	functional	scale,	as	well	as	6	multi-item	and	3	single-item	symptom	scale	[17].	The	functional	scales	include	General	Health	(GH),	Ability	to	Holiday	or
Travel	(HT),	Coping	(CO),	Physical	Function	(PF),	Ability	to	Eat	and	Drink	(ED),	Employment	(EM),	Sexual	Function	(SX),	and	Emotional	Function	(EF).	The	symptom	or	problem	scales	include	Body	Image	(BI),	Immobility	(IM),	Fatigue
(FA),	Sleep	Pattern	(SP),	Gastrointestinal	Symptoms	(GI),	other	Pain	(PA),	Presence	or	Absence	of	a	Stoma	(ST),	Financial	Issues	(FI),	and	Weight	(WT).	Two	questions	relate	to	nutrition	teams	and	the	availability	of	an	ambulatory	pump
for	infusion	of	HPN,	in	which	a	high	score	represents	a	good	outcome.	The	questionnaire	ends	up	with	three	0–10	numerical	rating	scales	(NRS)	where	high	scores	indicate	high	QOL.	The	first	is	a	global	QOL	question	and	the	other
two	respectively	assess	the	effect	of	the	underlying	illness	and	of	the	HPN	on	overall	QOL.	The	complete	English	version	of	the	questionnaire	can	be	found	in	the	appendix	of	the	present	paper	as	well	as	of	a	previously	published	paper
[17].
The	questionnaire	was	completed	by	the	patients,	either	self-administered	or	by	interview,	either	at	a	scheduled	outpatient	visit	or	at	home	after	mail	delivery.
Socio-demographic	and	clinical	data	including	age,	gender,	educational	level,	marital	and	employment	status,	underlying	disease,	reason	for	HPN	(life	prolonging,	quality	of	life	improving	or	maintaining),	duration	of	HPN,
characteristics	of	the	HPN	program	(day	of	infusion	per	week	and	hours	of	individual	infusion)	and	functional	status,	were	collected	by	the	treating	clinicians.
The	study	was	conducted	with	full	regard	to	confidentiality	of	the	individual	patient.	Ethical	committee	approval	was	obtained	by	the	individual	HPN	centers	according	to	local	regulations.
2.3	Statistical	analysis
The	HPN-QOL©	was	scored	according	to	scoring	rules	previously	reported	[17].	When	more	than	50%	of	items	in	a	scale	or	for	the	whole	questionnaire	were	missing,	the	scale	score	or	the	questionnaire	were	dropped	from
analysis	on	a	patient	basis;	when	the	number	of	missed	items	was	≤50%	for	a	single	scale,	the	mean	of	the	completed	items	was	used	for	simple	imputation.	Scale	scores	were	rescaled	in	order	to	range	from	0	to	100	and,	to	further
improve	readability,	made	uniform	so	that	high	scores	indicate	“good	condition”	in	all	scales	(i.e	high	function/good	status	as	well	as	low	symptom	or	problem	intensity).
Psychometric	analyses	 (Aim	1	of	 the	study)	evaluated	the	 following	aspects:	data	completeness,	convergent/discriminant	validity	and	 internal-consistency	reliability.	Data	completeness	was	measured	by	the	percentages	of
missing	 scale	 scores.	 Convergent	 and	 discriminant	 validity	 were	 assessed	 through	multitrait-scaling	 analysis	 [18]	 which	 explores	 the	 relationships	 of	 each	 item	 and	 hypothesized	 scales.	 Convergent	 validity	 indicates	 a	 relevant
correlation	between	an	item	and	the	scale	it	belongs	to;	corrected	for	overlap	Pearson	correlation	coefficients	≥0.4	support	convergent	validity	[18].	Discriminant	validity	is	supported	whenever	a	correlation	between	an	item	and	its
hypothesized	scale	is	higher	than	the	correlation	with	the	other	scales.	Internal-consistency	reliability	of	multi-item	scales	was	measured	by	Cronbach's	alpha;	alpha	values	above	0.7	are	generally	regarded	as	acceptable	for	group
comparison	[18].	Psychometric	analyses	were	performed	on	the	overall	sample	and	within	the	three	largest	language	subsamples:	English,	French	and	Italian.	Items	not	fitting	with	the	predefined	psychometric	criteria	on	the	overall
sample	were	evaluated	for	dropping	or	modification.
Aims	2	and	3	of	the	study	were	addressed	with	the	use	of	a	multivariable	linear	regression	models	in	which	the	overall	QOL	assessment	identified	by	the	item	44	(how	has	your	QOL	been	in	the	last	week?)	was	handled	as	the
dependent	variable.	In	a	first	analysis	(“main	model”)	the	following	variables	were	considered	as	predictors:	HPN	treatment	duration	(classified	as	short	or	long	toward	a	24-month	cut	off	between	reversible	and	irreversible	intestinal
failure)	[7],	age	(as	continuous	covariate),	gender,	living	status,	functional	status,	presence	of	a	stoma,	language	and	underlying	disease	(all	as	categorical	covariates).	Modeling	Modelling	of	the	latter	variable	in	particular	was	optimized
by	first	coding	the	distinct	categories	and	then	backward	deleting	non-significant	ones.	The	purpose	was	to	avoid	redundant	categories	and	the	consequent	loss	of	statistical	power	when	testing	this	covariate.	Such	an	analysis	was
carried	out	in	the	set	of	451	records	with	complete	information.	A	second	analysis	(“extended	model”)	was	carried	out	in	a	set	of	424	records	adding	to	the	above	specified	predictors	a	number	of	HPN	details	(indication,	type	of	supply,
days	and	hours	of	infusion).	Although	of	clinical	interest,	these	features	mostly	reflected	treatment	characteristics	that	were	likely	tuned	on	patient	and	disease	characteristics	and	may	thus	originate	some	degree	of	confounding.	For
such	a	reason	we	followed	a	“two-step”	strategy,	whereby	the	first	model	was	aimed	at	exploring	prognostic	effects	of	patient	and	disease	characteristics,	the	second	one	at	exploring	the	effect	of	treatment	details	while	adjusting	for
the	other	factors.	Results	are	reported	in	terms	of	estimated	regression	coefficients	beta,	corresponding	95%	confidence	limits	(95%	CLs)	and	overall	p	values	at	the	Wald's	test,	respectively	for	the	main	and	extended	models.	The
conventional	two-sided	5%	level	was	chosen	as	the	threshold	of	statistical	significance.	Statistical	analyses	were	carried	out	with	SAS	(version	9.2,	SAS	Institute,	Cary,	NC)	and	R	software	(version	3.1.1,	R	Foundation	for	Statistical
Computing,	Vienna,	Austria)	and	STATA	(version	13).
3	Results
3.1	Patient	characteristics
Six	hundred	and	ninety-nine	patients	accepted	to	participate	into	the	study	and	returned	the	questionnaire.	Statistical	analyses	included	691	patients,	after	excluding	eight	questionnaires	with	more	than	50%	missing	items.
Most	patients	were	women,	with	a	median	age	of	54	years,	were	either	married	or	living	with	a	partner	and	had	received	at	least	compulsory	school	education.	The	most	frequent	underlying	diseases	were	Crohn's	disease,
motility	disorders	and	mesenteric	ischaemia.	The	main	reasons	for	HPN	was	to	prolong	life	or	to	improve	QOL.	Duration	of	HPN	infusion	was	<2	years	in	around	one	third	of	patients	and	>10	years	in	26.4%.	Regarding	functional
status,	around	one-third	of	patients	required	some	or	total	help.
Despite	various	reminders	to	participating	centres,	many	socio-demographic	and	clinical	data	collection	forms	were	not	returned	thus	resulting	in	missing	data	(see	Table	1).
3.2	Psychometric	evaluation	of	the	HPN-QOL©
Preliminary	multitrait-scaling	 and	 internal	 consistency	 analyses	 indicated	 a	 bad	 fit	 of	 items	 4	 (burden	 of	HPN),	 20	 (ability	 to	 socialize),	 30	 (nausea	 and	 vomiting)	 and	 41	 (bowel	movements)	with	 respect	 to	 the	 original
questionnaire	structure.	These	items	were	therefore	excluded	from	their	respective	scales	(CO,	PF,	GI	and	NoST)	and	regarded	as	single	item	scales	(Table	2).	The	two	0–10	NRS	items	assessing	the	effect	of	illness	and	the	effect	of	HPN
on	global	QOL	showed	11%	and	12%	of	missing	data,	respectively.	These	figures	match	with	results	from	the	previous	validation	study	where	patients	reported	a	difficulty	to	distinguish	between	the	effect	of	illness	and	of	HPN	on	QOL
[16].	For	these	reasons	the	two	items	were	dropped	from	the	analysis.
Table	1	Socio-demographic	and	clinical	patients	characteristics.
alt-text:	Table	1
N %
Overall 691 100.0
Gender
	Female 348 61.6
	Male 217 38.4
	Missing 126 –
Age,	years
	Median	(range) 54 (17–94)
Marital	status
	Married/with	partner 341 65.7
	Separated/divorced/widowed 55 10.6
	Single 123 23.7
	Missing 172 –
Living	status
	Alone 95 17.5
	With	family 413 76.2
	With	other	adults 34 6.3
	Missing 149 –
Education
	Less	than	compulsory 35 7.8
	Compulsory	school 189 42.4
	Post	compulsory 155 34.8
	University 67 15.0
	Missing 245 –
Employment
	Student 19 4.3
	Unemployed 107 23.9
	Homemaker 43 9.6
	Self	employed 7 1.6
	Part	time 51 11.4
	Full	time 60 13.4
	Retired 135 30.2
	Other 25 5.6
	Missing 244 –
Underlying	Disease
	Cancer 38 6.3
	Crohn	disease 158 26.3
	Mesenteric	ischaemia 102 16.9
	Motility	disorders 105 17.4
	Radiation	Enteritis 47 7.8
	Other 152 25.3
	Missing 89 –
Predominant	indication	for	HPN
	Short	gut 346 60.8
	Fistula 12 2.1
	Obstruction 122 21.4
	Other 89 15.7
	Missing 122 –
HPN	duration
	1–2	months 9 1.5
	3–12	months 93 15.5
	13–24	months 95 15.8
	25–60	months 119 19.9
	61–120	months 125 20.9
	more	than	120	months 158 26.4
	Missing 92 –
HPN	supply
	Total 165 29.4
	Supplemental 397 70.6
	Missing 129 –
HPN	days	of	infusion	per	week
	Median	(range) 5.6 (2–7)
	Missing 128
HPN	hours	of	infusion	per	day
	2–11	h 190 31.8
	12–13	h 290 48.5
	More	than	13	h 118 19.7
	Missing 93
Functional	status
	Independent 425 70.3
	Some	help 143 23.6
	Total	help 37 6.1
	Missing 86 –
Country
	United	Kingdom 127 18.4
	Italy 117 16.9
	United	States 81 11.7
	France 76 11.0
	Netherlands 64 9.3
	Spain 43 6.2
	Germany 40 5.8
	Belgium 35 5.1
	Poland 35 5.1
	Canada 32 4.6
	Denmark 20 2.9
	New	Zealand 12 1.7
	Australia 9 1.3
	Missing – –
Abbreviations:	HPN:	home	parenteral	nutrition,	QOL:	quality	of	life.
Table	2	Results	of	Item	Scaling	and	Reliability:	overall	samplea.
alt-text:	Table	2
Scale kb Mean SD Missing	% Item-Internal	Consistencyc Item-Discriminant	Validityd Reliabilitye
Immobility	(IM) 5 68 25 1 0.50–0.73 0.03–0.49 0.84
Emotional	Function	(EF) 4 63 25 0 0.60–0.66 0.02–0.48 0.81
Physical	Function	(PF) 3 48 26 6 0.52–0.69 −0.04–0.59 0.78
Ability	to	Holiday/Travel	(HT) 2 34 26 5 0.83 0.01–0.30 0.91
Coping	(CO) 2 58 27 2 0.57 0.07–0.57 0.73
Ability	to	Eat/Drink	(ED) 2 62 26 4 0.55 −0.04–0.36 0.71
Employment	(EM) 2 36 32 5 0.49 −0.09–0.36 0.65
Sexual	Function	(SF) 2 22 25 17 0.63 −0.07–0.25 0.77
Body	Image	(BI) 2 66 33 1 0.76 −0.01–0.44 0.86
Fatigue	(FA) 2 52 31 0 0.84 0.01–0.55 0.91
Gastrointestinal	Symptoms	(GI) 2 64 29 4 0.49 −0.07–0.29 0.66
Pain	(PA) 2 64 29 0 0.48 0.04–0.41 0.65
Presence	of	Stoma	(ST) 2 70 29 3 0.70 −0.05–0.39 0.82
Absence	of	Stoma	(noST) 2 79 26 5 0.38 −0.01–0.38 0.54
Nutrition	Team	(NT) 1 77 31 4 – −0.05–0.14 –
Ambulatory	Pump	(AP) 1 65 36 0 – −0.02–0.22 –
General	Health	(GH) 1 75 24 2 – 0.06–0.32 –
Weight	(WT) 1 70 33 0 – −0.05–0.38 –
Sleep	Pattern	(SP) 1 60 35 0 – 0.01–0.35 –
Financial	Issue	(FI) 1 75 32 6 – −0.09–0.26 –
Burden	of	HPN	(item	4) 1 66 30 1 – 0.05–0.50 –
Ability	to	socialize	(item	20) 1 50 33 2 – −0.10–0.23 –
Nausea	and	vomiting	(item	30) 1 74 32 0 – 0.06–0.35 –
Bowel	movements	(no	stoma)	(item	41) 1 46 33 5 – −0.29–0.19 –
QOL	Numeric	Rating	Scale	(NRS) 1 58 21 3 – 0.14–0.53 –
a n	=	691.
bNumber	of	items.
c Range	of	correlations	between	items	in	the	scale.
d Range	of	correlations	between	each	item	in	the	scale	and	other	scales.
e Internal-consistency	reliability	(Cronbach's	alpha).
Results	 of	 psychometric	 analyses	 carried	 out	 on	 the	modified	 questionnaire	 structure	 are	 shown	 in	 Table	 2.	 Most	 scale-specific	 average	 scores	 were	 consistently	 around	 60	 to	 70,	 with	 the	 exception	 of	 sexual	 function,
holiday/travel,	 employment	 and	physical	 function	which	 scored	below	50.	 Item	 level	missing-value	 rates	 -not	 shown	 in	Table	2-	were	 low,	 ranging	 from	0%	 to	 6%,	 except	 for	 the	 two	 items	 related	 to	 sex	 (17%	and	20%	missing).
Accordingly,	completeness	was	good	for	most	scales	(Table	2),	the	only	exception	being	sexual	function	(17%	of	missing),	likely	because	of	sensitivity	issues	in	this	area	for	some	patients.	Lower	boundaries	of	item-internal	consistency
ranges	indicate	that	all	items	in	the	questionnaire	showed	a	satisfactory	correlation	with	their	own	scale	(≥0.4),	with	the	only	exception	of	items	42	(“difficulty	with	bowel	movements”)	and	43	(“painful	bowel	movements”)	in	the	No-
stoma	scale	(0.38	internal	correlation).	Item-discriminant	validity	correlation	figures	(Table	2)	were	also	satisfactory	for	all	the	comparisons	performed.	QOL	NRS	in	particular	yielded	a	median	correlation	with	other	scales	of	0.32,	data
not	reported	in	table	(range	0.14–0.53,	5	correlations>0.4).	Internal	consistency	reliability	was	good	for	most	of	the	multi-item	scales,	with	Cronbach's	α	coefficients	generally	higher	than	the	0.70	benchmark,	or	only	slightly	below	the
benchmark	for	EM	(α	=	0.65),	GI	(α	=	0.66),	PA	(α	=	0.65)	and	noST	(α	=	0.54).
Psychometric	evaluation	of	the	HPN-QOL©	in	the	different	English,	French	and	Italian	language	patient	sub-groups	(Supplementary	Tables	A1,	A2	and	A3)	provided	results	similar	to	those	in	the	overall	sample,	thus	confirming
the	good	quality	of	these	cultural	adaptations.
3.3	Investigation	of	QOL	associated	factors
Results	of	the	multivariable	linear	regression	modelling	are	shown	in	Table	3.	In	the	“main	model”	age,	gender,	functional	status,	presence	of	stoma	and	language	failed	to	achieve	statistical	significance.	Better	overall	QOL
scores	were	observed	in	patients	with	HPN	duration	longer	than	24	months	compared	to	patients	with	shorter	duration	(beta	=	0.55,	95%	CL:	0.12,	0.98;	P	=	0.013).	With	the	procedure	described	in	the	Methods	Section,	two	clusters
were	detected	for	underlying	disease	in	terms	of	outcome.	Better	QOL	was	observed	in	patients	with	Crohn	disease	or	mesenteric	ischaemia	compared	to	patients	with	other	diseases	(cancer,	motility	disorders,	radiation	enteritis	or
unspecified	conditions).	The	corresponding	beta	coefficient	was	0.65	(95%	CL:	0.25,	1.06;	P	=	0.002).	As	regards	living	status,	patients	living	alone	tended	to	be	disadvantaged	in	terms	of	QOL	outcome	compared	to	patients	not	living
alone	(beta	=	−0.64,	95%CL:	−1.18,	−0.10;	P	=	0.021).	The	whole	profiles	of	standardized	scale-specific	scores	according	to	HPN	duration,	underlying	disease	and	living	status	are	shown	in	Figs.	1–3.	Out	of	20	scales,	a	higher	score
was	observed	in	11	scales	in	patients	with	an	HPN	duration	>2	years,	in	16	of	those	with	Crohn's	disease	or	mesenteric	ischemia	ischaemia	and	in	12	of	those	not	living	alone.
Table	3	Results	from	the	multivariable	regression	modelling	used	to	investigate	the	factors	associated	with	overall	QOL.
alt-text:	Table	3
Category	(reference) Beta	(95%	CI) P
Main	model	(N	=	451)a
Age,	years
	IQ	range:	44–64 −0.9	(−3.6–1.9) 0.543
Gender
	Male	(female) 0.4	(−3.7–4.4) 0.862
Underlying	disease
	Crohn/Ischaemia	(other) 6.5	(2.5–10.6) 0.002
Living	status
	Alone	(not	alone) −6.4	(−11.8–−1.0) 0.021
Functional	status
	Some	help	(independent) −1.6	(−6.3–3.1) 0.700
	Total	help	(independent) 1.6	(−6.8–9.9)
Stoma
	Yes	(no) −3.7	(−7.7–0.3) 0.073
HPN	duration
	Long	(short) 5.5	(1.2–9.8) 0.013
Language
	French	(English) 3.6	(−2.1–9.3) 0.053
	Italian	(English) −3.1	(−8.9–2.6)
	Other	(English) 3.8	(−1.6–9.2)
Extended	model	(N	=	424)b
Indication
	Obstruction	(short	gut) −1.3	(−7.7–5.2) 0.468
	Other/fistula	(short	gut) −4.1	(−10.7–2.5)
HPN	supply
	Total	(supplemental) 2.2	(−2.8–7.2) 0.392
HPN	days	of	infusion	per	week
	IQ	range:	4–7 −4.7	(−8.9–−0.5) 0.028
HPN	hours	of	infusion	per	day
	12–13	(<12) −5.1	(−10.5–0.3) 0.140
	>13	(<12) −5.7	(−12.2–0.8)
Abbreviations:	QOL:	quality	of	life,	CI:	confidence	interval,	IQ:	interquartile,	HPN:	home	parenteral	nutrition.
aMain	model:	HPN	characteristics	excluded	because	dependent	on	the	underlying	disease.
b Extended	model:	assessment	of	the	HPN	characteristics	adjusted	for	the	remaining	factors.
The	“extended	model”,	 investigating	 the	 role	of	 the	HPN	characteristics	adjusted	 for	 the	other	 factors	 showed	a	 significant	 result	 only	 for	HPN	days	of	 infusion	per	week.	 In	particular,	 the	negative	coefficient	denoted	a
worsening	overall	QOL	for	an	increasing	number	of	infusion	days.
4	Discussion
This	paper	represents	the	final	step	of	a	research	on	QOL	of	HPN	patients	carried	out	on	behalf	 the	HAN&CIF	Special	 Interested	Group	of	ESPEN.	It	started	with	a	review	of	the	 instruments	used	to	assess	QOL	of	adult
patients	with	CIF	receiving	HPN	and	an	evaluation	of	the	state	of	art	of	this	topic	[3,19]	and	then	progressed	with	generation	of	QOL	issues,	production	of	a	provisional	questionnaire	and	its	pre-testing	[16].	The	scale	structure	of	the
questionnaire	was	initially	tested	with	regard	to	reliability	and	validity	in	a	preliminary	sample	of	100	patients	and	showed	positive	results	under	the	psychometric	and	clinical	profile	[17].
Fig.	1	Profiles	of	standardized	scale	scores	according	to	HPN	duration.
alt-text:	Fig.	1
Fig.	2	Profiles	of	standardized	scale	scores	according	to	underlying	disease.
alt-text:	Fig.	2
Fig.	3	Profiles	of	standardized	scale	scores	according	to	living	status.
alt-text:	Fig.	3
The	present	 study	went	 further	by	analyzing	 the	psychometric	properties	of	 the	questionnaire	 in	a	wider	multi-language	sample.	 In	particular,	multitrait-scaling	and	 internal	 consistency	analyses	 indicated	a	good	 fit	with
respect	to	the	original	questionnaire	structure	for	most	items.	Exceptions	were	items	4	(burden	of	HPN),	20	(ability	to	socialize),	30	(nausea	and	vomiting)	and	41	(bowel	movements)	which	failed	to	upload	to	their	respective	scales	and
had	to	be	considered	as	separate	single	item	scales.	Also	items	42	(“difficulty	with	bowel	movements”)	and	43	(“painful	bowel	movements”)	in	the	No-stoma	scale	showed	borderline	internal	correlation	(0.38).	The	explanation	for	the
poor	consistency	of	these	items	is	only	hypothetical	and	probably	reflects	the	heterogeneity	of	patients	population	on	HPN.	For	instance,	patients	with	a	low	burden	of	disease-related	symptoms	may	overestimate	the	burden	related	to
the	management	of	HPN.	In	contrast,	patients	requiring	intensive	treatment	of	their	primary	disease/condition	may	understand	HPN	as	an	invaluable	help	and	willingly	accept	it.	A	similar	explanation	may	apply	for	the	items	regarding
“bowel	movements”	since	some	patients	(i.e.	those	on	HPN	for	chronic	intestinal	obstruction)	may	consider	“frequent	bowel	movements”	as	positive,	whereas	for	others	(e.g.	patients	with	short	bowel	syndrome)	it	might	indicate	the
need	for	an	 increase	of	 the	HPN	volume,	hours	and/or	days	of	 infusion	to	compensate	 for	 the	excessive	 fluid	 loss.	 Item	discriminant	validity	analysis	showed	satisfactory	correlation	 figures	 for	all	 the	comparisons	performed;	 this
confirms	the	non-overlapping	meaning	of	distinct	scales.	Finally	psychometric	evaluation	of	the	HPN-QOL©	in	the	English,	French	and	Italian	language	patient	sub-groups	provided	results	quite	similar	to	those	in	the	overall	sample,
thus	confirming	the	psychometric	equivalence	of	the	questionnaire	in	the	three	language	versions.
The	“main	model”	of	the	multivariable	linear	regression	showed	that	QOL	score	was	significantly	dependent	on	the	type	of	the	underlying	disease,	the	duration	of	the	HPN	treatment	and	the	living	status.	The	“extended	model”
indicated	that,	when	adjusted	for	factors	identified	by	the	“main	model”,	the	number	of	days	of	HPN	per	week	has	also	a	significant	 impact	of	QOL.	Better	QOL	scores	were	observed	in	patients	with	Crohn	disease	or	mesenteric
ischemia	ischaemia	compared	 to	 patients	with	 other	 kinds	 of	 disease	 (cancer,	motility	 disorders,	 radiation	 enteritis	 or	 unspecified	 conditions).	 By	 showing	better	 overall	QOL	 in	 patients	with	 longer	HPN	duration,	 this	 study	 is	 in
agreement	with	the	results	of	previous	works	[20,21]	 indicating	that	patients	are	able	to	cope	with	their	 illness	over	time	with	a	possible	 improvement	 in	QOL.	Although	reasonable,	 this	 interpretation	must	be	taken	with	caution
considering	that	the	cross-sectional	study	design	does	not	allow	the	more	direct	assessment	of	time	trends	that	would	be	possible	with	a	longitudinal	design.	As	a	matter	of	fact,	the	QOL	is	influenced	by	the	gastrointestinal	illness	and
the	effects	of	HPN	treatment.	To	disentangle	these	effects,	it	would	be	necessary	to	prospectively	study	QOL	scores	in	a	cohort	of	patient	candidate	to	HPN	prior	and	after	HPN.	Such	a	kind	of	evidence	cannot	be	achieved	by	a	cross-
sectional	study	like	the	present	one.	The	finding	that	living	alone	is	associated	with	worst	QOL	scores	was	also	expected	and	can	be	explained	by	the	complex	technology	of	HPN	administration	that	requires	expertise	in	managing
aseptic	 techniques	as	well	as	 the	 invaluable	role	of	an	always	available	caregiver.	Also,	 it	 is	expected	that	 the	population	as	a	whole	 living	alone	 is	associated	with	 lower	QOL.	A	number	of	studies	have	assessed	QOL	of	patients
requiring	HPN	but	their	results	cannot	be	compared	with	this	study,	as	the	majority	of	these	studies	relied	on	generic	QOL	tools	that	were	not	tailored	to,	or	validated	in	this	patient	population	[19].
The	actual	role	of	HPN	characteristics	on	QOL	of	patients	with	CIF,	such	as	days	of	infusion	per	week	and	hours	of	infusion	per	day,	is	a	key	question.	Indeed,	HPN	is	the	primary	therapy	of	CIF	and	therefore	is	dependent	on
the	characteristics	of	the	underlying	disease	as	well	as	pathophysiological	mechanism	of	CIF	[1].	In	a	previous	short	term	prospective	follow	up	study	on	a	small	patient	population,	where	QOL	assessment	was	performed	using	the	SF-
36,	a	generic	assessment	 tool,	 it	was	observed	 that	 the	 reduction	of	QOL	was	associated	with	an	 increase	of	HPN	days	of	 infusion	per	week.	That	 result	was	considered	 to	 represent	a	deterioration	of	 the	 intestinal	 failure	 [22].
Nevertheless,	this	study	demonstrates	that	when	adjusted	for	the	major	factors	influencing	QOL,	the	number	of	HPN	infusion	per	week	plays	a	significant	role.	This	would	be	in	agreement	with	data	of	a	study	on	patients	with	short
bowel	syndrome,	where	QOL	was	assessed	using	a	validated	SBS-QOLTM	scale	[23].	In	this	cohort	of	patients,	having	the	same	underlying	disease	characteristics,	the	reductions	of	the	volume	of	HPN	infusion	(and	therefore	of	hours
and/or	days	of	infusions)	were	associated	with	improvements	in	QOL	scores.	In	2014,	the	ESPEN	HAN&CIF	group	carried	out	an	international	multicentre	study	aimed	to	identify	the	top	3	most	important	outcome	indicators	(out	of	a
list	of	9	proposed),	according	to	patients'	perspectives	[24].	QOL	was	the	third	of	the	top	3	indicators,	the	incidence	of	catheter-related	infection	and	survival	rate	being	the	first	two.	Interestingly,	for	1	of	the	9	outcome	indicators
(freedom	and	independence),	there	was	a	significant	difference	among	patients	categories	based	on	HPN	regimen	(number	of	HPN	day	per	week)	and	on	HPN	experience.	Independence	was	rated	more	important	for	less	experienced
patients	(HPN	duration	<2	years).	Most	of	the	less	experienced	patients	received	HPN	7	days	per	week,	whereas	experienced	patients	had	between	3	and	6	HPN	days	per	week.	Concerning	the	HPN	regimen,	patients	with	6	or	7	HPN
days	consistently	found	independence	important.	This	was	not	the	case	for	patients	with	5	HPN	days	or	less	per	week	[24].	Patients	were	also	asked	to	propose	new	indicators.	Among	those,	two	new	indicators	related	to	QOL	were
identified	“keeping	the	problems	related	to	my	underlying	disease	as	low	as	possible”	and	“maximizing	HPN-free	days”	[24].	Overall,	our	results	and	those	from	previous	studies	suggest	that	the	burden	of	the	underlying	disease	would
play	a	primary	role	in	determining	QOL	of	patients	on	HPN	for	CIF	and	that,	after	optimizing	the	disease	control,	QOL	could	be	further	improved	by	reducing	the	HPN	burden	as	lower	as	possible.
There	are	a	few	limitations	of	this	study.	In	the	first	place,	information	on	socio-demographic	and	clinical	data	was	not	complete	for	35.5%	of	the	patients	originally	entered	into	the	study.	This	was	due	to	administrative	problem
in	some	centres	which	performed	only	patient	reported	outcome	assessment	with	HPN-QOL©.	Secondly,	 in	spite	of	the	considerable	overall	sample	size,	the	number	of	patients	for	some	language	versions	(German,	Dutch,	Danish,
Polish	and	Spanish)	was	too	small	for	allowing	distinct	psychometric	testing.	More	language	specific	data	will	be	likely	available	if	the	HPN-QOL©	becomes	embedded	into	routine	clinical	practice.	The	measurement	of	QOL	should	be
included	in	the	list	of	clinical	quality	indicators	identified	as	part	of	the	global	attempt	at	raising	the	quality	of	clinical	care	[19];	particularly	since	most	patients	were	provided	with	HPN	to	either	maintain	or	improve	QOL.	Finally,	this
study	design	could	not	address	HPN-QOL©	questionnaire's	test-retest	reliability	and	responsiveness	to	change,	and	these	aspects	will	have	therefore	to	be	assessed	in	future	studies.
In	conclusion,	this	investigation	sought	to	respond	to	the	lack	of	evidence	regarding	QOL	assessment	in	patients	undergoing	HPN,	and	thus	has	the	potential	to	integrate	ESPEN	guidelines.	The	results	have	both	theoretical	and
practical	implications.	Many	clinical	services	are	inviting	patients	to	respond	to	Patient	Reported	Outcome	Measures	including	QOL	and	satisfaction	with	the	service	they	receive.	By	embedding	the	assessment	of	QOL	into	routine
clinical	care	clinicians	will	be	provided	with	the	necessary	outcome	evidence	that	ensures	good	‘patient	centred	care	[25].
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